Akari rises on rare pediatric disease designation for blood disorder drug

Akari Therapeutics

10/11/2022 13:36

** Akari Therapeutics Plc's shares  AKTX.O  rise 7.8% to
$0.55 before the bell
    ** U.S. FDA grants rare pediatric disease designation to
AKTX's experimental drug to treat rare blood disorder associated
with bone marrow transplant  urn:newsml:reuters.com:*:nGNX9hrt9z
    ** Designation to enable speedy review process during
marketing approval
    ** Up to Wednesday's close, stock had fallen ~66% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))